<code id='2C14BEBB7E'></code><style id='2C14BEBB7E'></style>
    • <acronym id='2C14BEBB7E'></acronym>
      <center id='2C14BEBB7E'><center id='2C14BEBB7E'><tfoot id='2C14BEBB7E'></tfoot></center><abbr id='2C14BEBB7E'><dir id='2C14BEBB7E'><tfoot id='2C14BEBB7E'></tfoot><noframes id='2C14BEBB7E'>

    • <optgroup id='2C14BEBB7E'><strike id='2C14BEBB7E'><sup id='2C14BEBB7E'></sup></strike><code id='2C14BEBB7E'></code></optgroup>
        1. <b id='2C14BEBB7E'><label id='2C14BEBB7E'><select id='2C14BEBB7E'><dt id='2C14BEBB7E'><span id='2C14BEBB7E'></span></dt></select></label></b><u id='2C14BEBB7E'></u>
          <i id='2C14BEBB7E'><strike id='2C14BEBB7E'><tt id='2C14BEBB7E'><pre id='2C14BEBB7E'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:96
          Andrew Trister, an oncologist and veteran of big technology companies and research, is Verily's new chief scientific officer.

          As Verily aims to get on track, the Alphabet life science company has hired Andrew Trister, an oncologist and veteran of big technology companies and research, as its new chief scientific officer.

          Trister will lead Verily’s population health initiatives, including public health solutions like the company’s ongoing work to combat disease-carrying mosquito populations and a program that helps wastewater treatment plants monitor for pathogens. He will also consult across Verily’s diverse projects.

          advertisement

          Trister’s focus on public health will build on his recent role as a deputy director at the Bill and Melinda Gates Foundation, where he led digital health, including a project to build tech infrastructure to help with malaria testing. Trister also led the foundation’s Covid-19 response. In 2016, he was an early health hire at Apple. There, he worked on programs like a heart health study with Janssen, an app to promote healthy habits with Aetna, and research into digital biomarkers for Alzheimer’s disease with Eli Lilly and Evidation.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          H.R. 3 is the wrong path to lower drug costs
          H.R. 3 is the wrong path to lower drug costs

          Fromleft,Rep.RichardNeal(D-Mass.)speaksasRep.FrankPallone(D-N.J.)andHouseSpeakerNancyPelosi(D-Calif.

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          The cancer stories no one wants to hear

          KARL-JOSEFHILDENBRAND/AFP/GettyImagesDuringthe11monthswhenmyhusband,Ahmad,wasdyingofbladdercancer,fe